Feasibility of a Novel Anti–BCMA-CAR Construct for Relapsed and Refractory Light Chain Amyloidosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Feasibility of a novel academic BCMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis
Clin. Cancer Res 2022 Sep 15;[EPub Ahead of Print], S Kfir-Erenfeld, N Asherie, S Grisariu, B Avni, E Zimran, M Assayag, T Dubnikov Sharon, M Pick, E Lebel, A Shaulov, YC Cohen, I Avivi, CJ Cohen, P Stepensky, ME GattFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.